Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2010 - 2025)

Fennec Pharmaceuticals has reported Total Non-Current Liabilities for 14 years, with the latest figure at $24.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 44.05% year-over-year to $24.6 million; the trailing twelve-month figure through Dec 2025 stood at $24.6 million (down 44.05% YoY), and the FY2025 full-year result was $24.6 million, down 44.05% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $24.6 million, down from $43.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $56.8 million in Q2 2024, with the low at $4.0 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $29.0 million across 5 years, with a median of $25.4 million in 2023.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 536.24% — and 2025, when it slumped 44.05%.
• Fennec Pharmaceuticals' Total Non-Current Liabilities stood at $5.0 million in 2021, then soared by 399.18% to $24.9 million in 2022, then climbed by 24.23% to $30.9 million in 2023, then soared by 41.92% to $43.9 million in 2024, then tumbled by 44.05% to $24.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $24.6 million (Q4 2025), $43.9 million (Q3 2025), and $43.9 million (Q2 2025), per Business Quant data.